Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAVE versus GVE in previously untreated high-risk chronic lymphocytic leukemia
2020-004360-26Phase 3Active
- Sponsor
- German CLL Study Group
- Start
- Jun 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of acalabrutinib, obinutuzumab and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by German CLL Study Group. Primary endpoint: Progression-free survival. Started Jun 2021; status: active.
02
Drugs
acalabrutinibobinutuzumabvenetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2020-004360-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004360-26.